In vivo drug-selectable markers in gene therapy

Leukemia. 1997 Apr:11 Suppl 3:552-6.

Abstract

Two-gene vectors with positive or positive-negative drug-selectable markers enable the expansion or elimination of gentetically modified cells in vivo. We have established a bicistronic retroviral vector system which utilizes an internal ribosome entry site (IRES) to co-express two independent genes with high efficiency. As a positive-negative (suicide) marker, Herpes simplex virus thymidine kinase was co-expressed with the human multidrug resistance gene, MDR1. Using this vector, almost all the MDR1-transduced cells showed hypersensitivity to a nucleoside analog, ganciclovir. As a dominant selectable marker, the MDR1 gene was co-expressed with alpha-galactosidase A for the model of gene therapy of Fabry disease. Vincristine selection efficiently enhanced the population of transduced cells expressing the second non-selectable genes. These drug-selectable retroviral vectors could be applicable to the therapy of many diseases.

MeSH terms

  • 3T3 Cells
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / biosynthesis
  • Animals
  • Drug Resistance, Multiple / genetics*
  • Genetic Diseases, Inborn / therapy
  • Genetic Markers*
  • Genetic Therapy / methods*
  • Genetic Vectors
  • Harvey murine sarcoma virus
  • Humans
  • Mice
  • Repetitive Sequences, Nucleic Acid
  • Retroviridae
  • Ribosomes / metabolism
  • Simplexvirus / enzymology
  • Simplexvirus / genetics
  • Thymidine Kinase / biosynthesis
  • Thymidine Kinase / genetics*
  • Transfection / methods
  • alpha-Galactosidase / biosynthesis
  • alpha-Galactosidase / genetics

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Genetic Markers
  • Thymidine Kinase
  • alpha-Galactosidase